FOURIER Trial Reveals Significant Reduction in Cardiovascular Risk

WASHINGTON, D.C., March 17, 2017 —  The FOURIER trial lead investigators announced today that the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events by 15%. The detailed results from the FOURIER outcomes trial were presented at the American College of Cardiology’s 66th Annual Scientific Session Friday, March 17 in Washington, D.C. While PCSK9 inhibitors have proven success in reducing LDL-C, those studies lacked outcomes and long-term safety data.